Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia.

Autor:	Piñeyroa JA; Department of Hematology, Hospital Clínic, Barcelona, Spain., Magnano L; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Rivero A; Department of Hematology, Hospital Clínic, Barcelona, Spain., Rivas-Delgado A; Department of Hematology, Hospital Clínic, Barcelona, Spain., Nadeu F; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Correa JG; Department of Hematology, Hospital Clínic, Barcelona, Spain., Giné E; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Villamor N; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain., Filella X; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Biochemistry and Molecular Genetics, Hospital Clínic, Barcelona, Spain., Colomer D; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain.; Universitat de Barcelona, Barcelona, Spain., López M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain., López-Oreja I; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain., Costa D; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain., Aymerich M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain., Beà S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain.; Universitat de Barcelona, Barcelona, Spain., López-Guillermo A; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Universitat de Barcelona, Barcelona, Spain., Campo E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain.; Universitat de Barcelona, Barcelona, Spain., Delgado J; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Universitat de Barcelona, Barcelona, Spain., Mozas P; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Hematological oncology [Hematol Oncol] 2022 Oct; Vol. 40 (4), pp. 588-595. Date of Electronic Publication: 2022 May 28.
DOI:	10.1002/hon.3027
Abstrakt:	Serum soluble CD23 (sCD23) levels have been acknowledged as a prognostic factor in patients with chronic lymphocytic leukemia (CLL), but their potential relevance has not been analyzed in recent times. We retrospectively studied 338 CLL, small lymphocytic lymphoma, or CLL-type monoclonal B-cell lymphocytosis patients from a single institution, with available sCD23 levels at diagnosis. Baseline features and outcomes were compared between patients with sCD23 ≤/>1000 UI/L. The 140 patients (41%) who had sCD23 > 1000 UI/L showed adverse-risk clinical and biological characteristics. High sCD23 levels were predictive of a shorter time to first treatment (5-year probability of requiring treatment: 60 vs. 20%, p < 0.0001; hazard ratio (HR) = 1.72, p = 0.003 in a multivariable model also including the CLL International Prognostic Index and the absolute lymphocyte count), and a poorer 5-year overall survival (70 vs. 82%, p = 0.0009). These data suggest the potential of sCD23 to predict treatment-free survival and to shed light on mechanisms of activity and resistance to CD23-directed therapies. (© 2022 John Wiley & Sons Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text